Association of MiR-146a Expression and Type 2 Diabetes Mellitus: A Meta-Analysis

Overview

Journal Int J Mol Cell Med

Specialty Genetics

Date 2018 Apr 24

PMID 29682487

Citations 32

Authors

Behnam Alipoor

Hamid Ghaedi

Reza Meshkani

Shahram Torkamandi

Sana Saffari

Mostafa Iranpour

Mir Davood Omrani

Affiliations

Soon will be listed here.

Abstract

Although deregulation of miR-146a has been reported in type 2 diabetes repeatedly, the direction of deregulation events (up or down) remained to be inconsistent in literatures. Therefore, in this study we performed a meta-analysis on the possible association between miR-146a expression levels and type 2 diabetes. A systematic literature searching of PubMed, ISI Web of Science and Google Scholar was performed up to the end of September 2016. Finally, a total of 12 studies including 344 diabetic patients and 316 controls were selected for meta-analysis. All statistical analysis was performed using the metafor package with R software. Moreover, publication bias was assessed by Egger's and sensitivity analysis was applied on the meta-analysis. The results are presented as log10 odds ratios (logORs), 95% confidence intervals (CI) with relevant P values. The results revealed that miR-146a was downregulated in type 2 diabetes cases compared with normal subjects (P=0.01, logOR:-4.76, 95% CI:-8.41, -1.11). Furthermore, sub-group analysis showed that the association between miR-146a expression levels and type 2 diabetes in whole blood (P<0.001) and PBMCs (P<0.001) samples were significant. However, this association was not significant in the serum (P=0.67) and plasma (P=0.90) samples. Our finding suggests that miR-146a downregulation could be associated with type 2 diabetes susceptibility. Further investigations with larger sample size are required to evaluate this association in the type 2 diabetes pathogenesis.

Citing Articles

Exercise in Diabetic Cardiomyopathy: Its Protective Effects and Molecular Mechanism.

Chen H, Guo L Int J Mol Sci. 2025; 26(4).

PMID: 40003929 PMC: 11855851. DOI: 10.3390/ijms26041465.

Role of Decreased Expression of miR-155 and miR-146a in Peripheral Blood of Type 2 Diabetes Mellitus Patients with Diabetic Peripheral Neuropathy.

Ji H, Lu Y, Liu G, Zhao X, Xu M, Chen M Diabetes Metab Syndr Obes. 2024; 17:2747-2760.

PMID: 39072343 PMC: 11283243. DOI: 10.2147/DMSO.S467409.

Role of microRNAs in Diabetes-Associated Periodontitis: A Scoping Review.

Agnihotri R, Gaur S, Bhat S J Int Soc Prev Community Dent. 2024; 14(3):180-191.

PMID: 39055291 PMC: 11268527. DOI: 10.4103/jispcd.jispcd_3_24.

The Effect of Physical Activity/Exercise on miRNA Expression and Function in Non-Communicable Diseases-A Systematic Review.

Afzal M, Greco F, Quinzi F, Scionti F, Maurotti S, Montalcini T Int J Mol Sci. 2024; 25(13).

PMID: 38999923 PMC: 11240922. DOI: 10.3390/ijms25136813.

A Review of MicroRNAs and lncRNAs in Atherosclerosis as Well as Some Major Inflammatory Conditions Affecting Atherosclerosis.

Letonja J, Petrovic D Biomedicines. 2024; 12(6).

PMID: 38927529 PMC: 11201627. DOI: 10.3390/biomedicines12061322.

References

Balasubramanyam M, Aravind S, Gokulakrishnan K, Prabu P, Sathishkumar C, Ranjani H . Impaired miR-146a expression links subclinical inflammation and insulin resistance in Type 2 diabetes. Mol Cell Biochem. 2011; 351(1-2):197-205. DOI: 10.1007/s11010-011-0727-3. View

Karolina D, Armugam A, Tavintharan S, Wong M, Lim S, Sum C . MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 2011; 6(8):e22839. PMC: 3148231. DOI: 10.1371/journal.pone.0022839. View

Sood P, Krek A, Zavolan M, Macino G, Rajewsky N . Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A. 2006; 103(8):2746-51. PMC: 1413820. DOI: 10.1073/pnas.0511045103. View

Rong Y, Bao W, Shan Z, Liu J, Yu X, Xia S . Increased microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PLoS One. 2013; 8(9):e73272. PMC: 3759444. DOI: 10.1371/journal.pone.0073272. View

Duan X, Zhan Q, Song B, Zeng S, Zhou J, Long Y . Detection of platelet microRNA expression in patients with diabetes mellitus with or without ischemic stroke. J Diabetes Complications. 2014; 28(5):705-10. DOI: 10.1016/j.jdiacomp.2014.04.012. View

Baldeon R L, Weigelt K, de Wit H, Ozcan B, van Oudenaren A, Sempertegui F . Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients. PLoS One. 2014; 9(12):e115209. PMC: 4264887. DOI: 10.1371/journal.pone.0115209. View

Kong L, Zhu J, Han W, Jiang X, Xu M, Zhao Y . Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol. 2010; 48(1):61-9. DOI: 10.1007/s00592-010-0226-0. View

Corral-Fernandez N, Salgado-Bustamante M, Martinez-Leija M, Cortez-Espinosa N, Garcia-Hernandez M, Reynaga-Hernandez E . Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2013; 121(6):347-53. DOI: 10.1055/s-0033-1341516. View

Hayes J, Peruzzi P, Lawler S . MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014; 20(8):460-9. DOI: 10.1016/j.molmed.2014.06.005. View

10.

Bhatia P, Raina S, Chugh J, Sharma S . miRNAs: early prognostic biomarkers for Type 2 diabetes mellitus?. Biomark Med. 2015; 9(10):1025-40. DOI: 10.2217/bmm.15.69. View

11.

McClelland A, Kantharidis P . microRNA in the development of diabetic complications. Clin Sci (Lond). 2013; 126(2):95-110. DOI: 10.1042/CS20130079. View

12.

Saba R, Sorensen D, Booth S . MicroRNA-146a: A Dominant, Negative Regulator of the Innate Immune Response. Front Immunol. 2014; 5:578. PMC: 4240164. DOI: 10.3389/fimmu.2014.00578. View

13.

Frost R, Olson E . Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. Proc Natl Acad Sci U S A. 2011; 108(52):21075-80. PMC: 3248488. DOI: 10.1073/pnas.1118922109. View

14.

Ahlqvist E, van Zuydam N, Groop L, McCarthy M . The genetics of diabetic complications. Nat Rev Nephrol. 2015; 11(5):277-87. DOI: 10.1038/nrneph.2015.37. View

15.

Schulte C, Zeller T . microRNA-based diagnostics and therapy in cardiovascular disease-Summing up the facts. Cardiovasc Diagn Ther. 2015; 5(1):17-36. PMC: 4329169. DOI: 10.3978/j.issn.2223-3652.2014.12.03. View

16.

Zhu H, Leung S . Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia. 2015; 58(5):900-11. DOI: 10.1007/s00125-015-3510-2. View

17.

Guariguata L, Whiting D, Hambleton I, Beagley J, Linnenkamp U, Shaw J . Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014; 103(2):137-49. DOI: 10.1016/j.diabres.2013.11.002. View

18.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

19.

Raffort J, Hinault C, Dumortier O, Van Obberghen E . Circulating microRNAs and diabetes: potential applications in medical practice. Diabetologia. 2015; 58(9):1978-92. DOI: 10.1007/s00125-015-3680-y. View

20.

Khodabandehloo H, Gorgani-Firuzjaee S, Panahi G, Meshkani R . Molecular and cellular mechanisms linking inflammation to insulin resistance and β-cell dysfunction. Transl Res. 2015; 167(1):228-56. DOI: 10.1016/j.trsl.2015.08.011. View